Abstract: Compositions and reaction kits are provided for controlling an enzymatic process. The compositions and kits include a substantially water-insoluble, water-permeable polymer and a poorly water-soluble salt of an essential ionic enzymatic reactant. The disclosed compositions and methods are particularly useful for improving the specificity and performance of PCR.

Abstract: Translationally competent ribosomes are bound to a solid substrate through a specific attachment site. A spatial array of such immobilized ribosomes may be produced on a planar substrate, microbeads, on fiber optics. One or more components of the ribosome complex are preferably labeled, e.g. with a fluorescent dye. Ribosomal RNAs, including mRNA and tRNA; and/or ribosomal proteins may be labeled at specific positions, and arrays of immobilized ribosomes may comprise a panel of different labels and positions of labels. Fluorescence detection can then be used to monitor conformational dynamics and translation rates.

Abstract: Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation.

Abstract: Methods are provided for quenching undesired side reactions of pathogen inactivating compounds in biological materials comprising red blood cells. In a particular embodiment, methods are provided for quenching undesired side reactions of a pathogen inactivating compound that includes a functional group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. The electrophilic group on the pathogen inactivating compound is preferably a non-radical cationic group. In one embodiment, the pathogen inactivating compound includes a nucleic acid binding ligand and a mustard group, wherein the mustard group is capable of reacting in situ to form the electrophilic group. Preferred quenchers are thiols, such as glutathione.

Abstract: Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells may be red blood cells or blood platelets.

Abstract: The present invention is directed to methods and compositions regarding the preparation of an cell concentrate, such as, for example, an osteogenic cell concentrate, from a physiological solution, such as bone marrow aspirate, blood, or a mixture thereof. In specific embodiments, the invention provides methods and compositions utilizing two physiological solution-processing techniques, particularly in a point of care environment, wherein centrifugation is not employed.

Abstract: The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-?-1?4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis.

Abstract: The present invention provides a method that maintains chondrocyte phenotype during serial expansion by culturing a population of chondrocytes in a defined serum-free culture medium containing cytokines and on a substrate that is modified by covalent attachment of hyaluronic acid. The underlying principle is to maintain native chondrocyte phenotype by growing the dissociated chondrocytes on a substrate modified by covalent attachment of hyaluronic acid to retain native chondrocyte morphology and function. Chondrocyte expanded in this manner can be used in various medical applications to repair cartilaginous tissues that have been injured by trauma or disease. This substratum provides a microenvironment that more closely mimics that of native articular cartilage, thereby promoting chondrogenesis in a predictable manner.

Abstract: The invention disclosed a kind of lactobacillus casei Bd-II, the accession number of the deposit of which is CGMCC NO.0849, and also disclosed a use of it for reducing blood lipid level. Further, a composition for reducing blood lipid level containing it and an acceptable carrier is disclosed. The carrier can be skimmed milk.

Abstract: A meat product containing in vitro produced animal cells in a three dimensional form and a method for producing the meat product.

Abstract: Living cellular material may be preserved by incubating the cellular material in a culture medium containing at least one sugar, particularly for at least three hours, and then subjecting the cellular material to a preservation protocol, such as freezing, vitrification, freeze-drying and desiccation.

Abstract: Mass spectrometric techniques are provided for detecting the presence of parasites that accumulate unbound heme in red blood cells (including malaria parasites), based on the discovery that unbound heme can be detected and quantified using mass spectrometry. In one aspect of the invention, the method includes the steps of: obtaining a blood sample from the animal; preparing a test sample on a support from the blood sample, and inserting the support into a mass spectrometer for analysis. Next one obtains a mass spectrum of the test sample and determines whether the mass spectrum contains a mass/charge signature of unbound heme. If it is determined that the mass spectrum of the test sample shows the mass/charge signature of unbound heme, the animal is diagnosed as infected with malaria parasites.

Abstract: A carrier for cell culture comprising a carrier having a cationic group and polypeptide-modified portions formed on a surface of the carrier in a sea-island structure, and a carrier for cell culture comprising a water-containing gel comprising alginic acid, wherein a surface of the carrier is coated with collagen, and wherein the collagen is bound to a surface of the water-containing gel by means of chitosan.

Abstract: A method of treatment of a patient includes administering to the patient stored red blood cells and a hemoglobin solution. The stored red blood cells and the hemoglobin solution can be administered to the patient simultaneously. Alternatively, the hemoglobin solution can be administered to the patient prior to administrating the stored red blood cells or the stored red blood cells can be administered to the patient prior to administering the hemoglobin solution. A composition of the invention includes stored red blood cells and a hemoglobin solution.

Abstract: Glycol ether acetates, and in particular propylene glycol alkyl (or aryl) ether acetates, can be resolved enzymatically by enantioselective hydrolysis with a hydrolase at high concentrations of substrates; in some embodiments, the hydrolase is a lipase. Glycol ethers, and in particular propylene glycol alkyl (or aryl) ethers, can be resolved enzymatically by enantioselective transesterification with a hydrolase, in the presence of an acyl donor, at high concentrations of substrates; in some embodiments, the hydrolase is a lipase.

Abstract: The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.

Abstract: The invention provides a cochineal color, a colorant product containing the cochineal color and the method of its production, wherein the cochineal color is free of allergenic proteins and contaminants derived from the raw material Coccus cacti L. insect and can be added with safety to products taken by mouth, such as foods, pharmaceutical products, etc. The invention relates to a cochineal color substantially free of proteins of molecular weight not less than 6000. The invention also relates to a process for producing a cochineal color which comprises subjecting a cochineal extract solution to proteolysis and then to at least one treatment selected from the group consisting of adsorption treatment, ion exchange treatment, acid treatment, extraction treatment and membrane treatment.

Abstract: This invention has as its object a process for generating the idiosyncratic catalytic imprint of a sample, characterized in that it comprises the following stages: the sample that is likely to have the catalytic activity is brought into contact with a group of substrates; the signals that are generated after said contact are captured in some way. Advantageously, after the signals are captured, a processing of the latter that consists of assigning to each signal a digital value constituting a component of a graphic display, for example a color display, of the idiosyncratic imprint is carried out.

Abstract: An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/L, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/L weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.

Abstract: Use of an association of lactobacilli for preparation of a pharmaceutical composition for treatment of vaginosis and vaginitis. Said bacteria association comprises the Lactobacillus brevis and Lactobacillus salivarius subs. salicinius species, possibly in combination with one or more species selected from Lactobacillus salivarius subs. salivarius, Lactobacillus jensenii, Lactobacillus catenaforme, Lactobacillus minutus and Lactobacillus gasseri. A pharmaceutical composition comprising said association of lactobacilli adapted for treatment of vaginosis and vaginitis. A method of treating vaginosis and vaginitis based on administration of said pharmaceutical composition.